Skip to main content

Cambium Bio Secures A$10.85 Million to Initiate Pivotal Phase 3 Trial of Elate Ocular®, a Potential First-in-Class Biologic for Dry Eye Disease

Written by Customer Service on . Posted in Public Companies.

Strategic shareholders commit A$7.1 million at a premium to market, the Company’s fourth consecutive equity raise priced at a premium, alongside A$3.75 million of non-dilutive R&D Tax Incentive pre-financing

SYDNEY, Sept. 16, 2026 (GLOBE NEWSWIRE) — Cambium Bio Limited (ASX: CMB) (“Cambium Bio” or the “Company”), a clinical-stage regenerative medicine company developing biologic therapies for ophthalmology, today announced that it has secured an A$10.85 million funding package to initiate its pivotal Phase 3 trial of Elate Ocular® in moderate to severe dry eye disease (“DED”). The package comprises A$7.1 million (US$5.0 million) in firm commitments from strategic shareholders through a placement priced at A$0.48 per share, a 4.3% premium to the last closing price, and an A$3.75 million secured facility that pre-finances the Company’s FY2027 Research and Development Tax Incentive refund.

Highlights

  • Strategic capital at a premium. A$7.1 million committed by strategic shareholders, extending a track record of raising capital at a premium.
  • Funding to initiate the pivotal trial. CAMOMILE-2 is a single 475-patient Phase 3 trial that the U.S. Food and Drug Administration (FDA) has confirmed is sufficient to support a Biologics License Application (BLA). Initiation is targeted for the fourth quarter of 2026.
  • A potential first-in-class biologic. Elate Ocular® is a biologic derived from human platelet lysate. To the Company’s knowledge, no biologic therapy has been approved for the treatment of dry eye disease, and Elate Ocular® has the potential to be the first. The program holds FDA Fast Track designation.
  • Clear path to registration. Topline data from the pivotal trial are targeted for late calendar 2027. Subject to the trial meeting its co-primary sign and symptom endpoints, the Company intends to file a BLA with the FDA in 2028.

Karolis Rosickas, Chief Executive Officer of Cambium Bio, said:

“Our strategic shareholders have once again backed Cambium Bio at a premium to market, and that support now gives us the funding to start the pivotal trial of Elate Ocular®. Dry eye disease still has no approved biologic therapy. With one pivotal trial agreed with the FDA, Fast Track designation and the funding in place to initiate that trial, our path is clear: topline data in late 2027 and a BLA filing in 2028.”

The placement is conditional on shareholder approval at the Company’s 2026 Annual General Meeting. Full details are in the Company’s ASX announcement dated 16 September 2026 at www.asx.com.au.

About Cambium Bio Limited

Cambium Bio Limited (ASX: CMB) is a Sydney-based clinical-stage regenerative medicine company developing biologics for ophthalmology and tissue repair from its proprietary human platelet lysate technology. Its lead product candidate, Elate Ocular®, is being developed for moderate to severe dry eye disease.

Contact

Karolis Rosickas, Chief Executive Officer
info@cambium.bio

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.